ImmunityBio (IBRX)

Executive Summary

ImmunityBio is a clinical-stage biotechnology company that has achieved a key milestone with the FDA approval of ANKTIVA (nogapendekin alfa inbakicept-pmln), a first-in-class IL-15 superagonist for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) in April 2024. The company, founded by Dr. Patrick Soon-Shiong, focuses on activating multiple immune pathways through a pipeline of novel immunotherapies, including cytokine fusions, NK cell therapies, and cancer vaccines. ANKTIVA's approval positions ImmunityBio in the bladder cancer market, with ongoing efforts to expand its label and explore combinations with checkpoint inhibitors. Beyond ANKTIVA, ImmunityBio's pipeline includes several advanced-stage trials. The Phase 2/3 QUILT-3.032 study (NCT03022825) evaluates N-803 (ANKTIVA) plus BCG in BCG-naïve NMIBC, with completion expected by 2029, though interim data may emerge sooner. A Phase 3 trial (NCT03520686) is testing a multi-drug regimen including N-803 in non-small cell lung cancer, with primary completion in December 2026. Additionally, the Phase 1 trial of PD-L1 t-haNK (NCT04050709) for solid tumors is nearing completion. Key upcoming catalysts include label expansion updates for ANKTIVA, interim data from the QUILT-3.032 study, and initial results from the PD-L1 t-haNK trial, which could drive near-term value.

Upcoming Catalysts (preview)

• H1 2027Interim data from QUILT-3.032 Phase 2/3 trial of ANKTIVA + BCG in BCG-naïve NMIBC65% success
• H2 2026Label expansion or new indication data for ANKTIVA (e.g., combination with checkpoint inhibitors)50% success
• Q2 2026Phase 1 results for PD-L1 t-haNK cell therapy in solid tumors70% success